Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soheil Meshinchi

Showing results (161-170 of 218) with videos related to

Pageof 22
Sort By:
British Journal of Haematology|October 22, 2016
Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemiaFiona C Brown, Paolo Cifani, Esther Drill, et al.
The Lancet. Oncology|May 11, 2010
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trialJeffrey E Rubnitz, Hiroto Inaba, Gary Dahl, et al.
British Journal of Haematology|September 24, 2023
Treatment outcomes of childhood PICALM::MLLT10 acute leukaemiasCatherine Mark, Soheil Meshinchi, Brooklyn Joyce, et al.
Clinical Epigenetics|October 17, 2017
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AMLLia Gore, Timothy J Triche, Jason E Farrar, et al.
Blood|May 5, 2021
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology GroupKatherine Tarlock, Adam J Lamble, Yi-Cheng Wang, et al.
Cancers|April 27, 2024
Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 TrialAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council reportFabiana Ostronoff, Megan Othus, Michelle Lazenby, et al.
Blood|September 22, 2020
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG reportFieke W Hoff, Anneke D van Dijk, Yihua Qiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2017
MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid LeukemiaEmilia L Lim, Diane L Trinh, Rhonda E Ries, et al.
Biomarker Research|March 17, 2023
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patientsEra L Pogosova-Agadjanyan, Xing Hua, Megan Othus, et al.
Pageof 22

Showing results (161-170 of 218) with videos related to

Sort By:
Pageof 22
British Journal of Haematology|October 22, 2016
Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemiaFiona C Brown, Paolo Cifani, Esther Drill, et al.
The Lancet. Oncology|May 11, 2010
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trialJeffrey E Rubnitz, Hiroto Inaba, Gary Dahl, et al.
British Journal of Haematology|September 24, 2023
Treatment outcomes of childhood PICALM::MLLT10 acute leukaemiasCatherine Mark, Soheil Meshinchi, Brooklyn Joyce, et al.
Clinical Epigenetics|October 17, 2017
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AMLLia Gore, Timothy J Triche, Jason E Farrar, et al.
Blood|May 5, 2021
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology GroupKatherine Tarlock, Adam J Lamble, Yi-Cheng Wang, et al.
Cancers|April 27, 2024
Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 TrialAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council reportFabiana Ostronoff, Megan Othus, Michelle Lazenby, et al.
Blood|September 22, 2020
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG reportFieke W Hoff, Anneke D van Dijk, Yihua Qiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2017
MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid LeukemiaEmilia L Lim, Diane L Trinh, Rhonda E Ries, et al.
Biomarker Research|March 17, 2023
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patientsEra L Pogosova-Agadjanyan, Xing Hua, Megan Othus, et al.
Pageof 22